NEO:CYBN

News

Cybin Inc. Releases Financial Highlights and Provides Business Update

Cybin Announces Closing of Upsized Bought Deal Offering

Cybin Included in First Psychedelic Exchange Traded Fund

Cybin Announces Upsize to Previously Announced Bought Deal Offering

Cybin Announces CDN$20 Million Bought Deal Offering

Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Cybin Provides Update On Patent Filings & Development Of Therapeutics Program

Cybin Announces First Quarter Financial Results Of Clarmin Explorations Inc.

Cybin Closes Acquisition Of Adelia Therapeutics; Bolsters Scientific Team And Grows IP Portfolio To 7 Patent Filings

Cybin is a biotechnology company focused on progressing psychedelics therapeutics.

5600-100 King St W, Toronto,
ON M5X 1C9

PRIVACY POLICY

© Cybin INC. 2019 All rights reserved.